Patents by Inventor Om P. Srivastava

Om P. Srivastava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Equine Esomeprazole Formulations and Methods of Use
    Publication number: 20220354836
    Abstract: The present disclosure relates to formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium or esomeprazole magnesium dihydrate, and methods of use in treating ulcers in equines and other veterinary animals The disclosure also relates to injectable formulations of proton pump inhibitors such as omeprazole or esomeprazole including their salts or hydrated salts, such as esomeprazole sodium, esomeprazole magnesium, or esomeprazole magnesium dihydrate, which have a small particle size, such as a median particle size of less than 10 ?m or less than 5 ?m.
    Type: Application
    Filed: July 15, 2020
    Publication date: November 10, 2022
    Applicant: Kindred Biosciences, Inc.
    Inventors: Geeta Srivastava, Om P. Srivastava, Emily Sundman, Melinda Poole O'Banion
  • Oligosaccharide glycosides having mammalian immunosuppresive and tolerogenic properties
    Patent number: 5874411
    Abstract: Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: February 23, 1999
    Assignee: Glycomed Incorporated
    Inventors: Om P. Srivastava, Geeta Srivastava, Roman Szweda, David R. Bundle, Ole Hindsgaul, H. Rizk Hanna, Kevin Holme, Frank W. Barresi, Minghui Du
  • Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen
    Patent number: 5814616
    Abstract: The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.
    Type: Grant
    Filed: November 5, 1996
    Date of Patent: September 29, 1998
    Assignee: Alberta Research Council
    Inventors: Om P. Srivastava, Roman Szweda, Richard H. Smith, Robert M. Ippolito, Ulrike Spohr
  • Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
    Patent number: 5646123
    Abstract: Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammals. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type II core structure wherein the administration of such oligosaccharide glycosides is after initiation of the mammal's immune response but at or prior one-half the period of time required to effect maximal antigen-induced inflammation.
    Type: Grant
    Filed: March 17, 1995
    Date of Patent: July 8, 1997
    Assignee: Alberta Research Council
    Inventors: Robert M. Ippolito, Wasimul Haque, Cong Jiang, H. Rizk Hanna, Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem, Richard Smith, Om P. Srivastava
  • Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen
    Patent number: 5571796
    Abstract: The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 5, 1996
    Assignee: Alberta Research Council
    Inventors: Om P. Srivastava, Roman Szweda, Richard H. Smith, Robert M. Ippolito, Ulrike Spohr